Medifocus, Inc. (OTCQX: MDFZF)(TSX-V: MFS)develops and commercializes minimally invasive treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”). The Company owns two technology platforms with approximately 100 issued and pending US and international patents. Based on these proprietary technology platforms, the Company has developed two advanced therapeutic products: the Adaptive Phased Array (APA)-1000 system for treatment of breast cancer and the Prolieve® system for the treatment of BPH. SNNLive spoke with John Mon, COO of Medifocus Inc. at the 3rd Annual Marcum MicroCap Conference 2014 in New York City, NY.
“We have two really blockbuster products, one in the urology BPH business and the other one in the breast cancer business,” begins Mr. Mon. He continues, “They’re both in billion dollar market places, the first one is BPH treatment, benign prostatic hyperplasia, which is the enlargement of the male’s prostate gland” and “we have a quick outpatient 45 minute treatment that can give instant relief and better quality of life.”
“This technology came from star wars technology from MIT, it was developed for focusing microwaves on missiles to destroy missiles” explains Mr. Mon. He adds,” We’re focusing microwaves from outside the breast to inside the breast to the tumor, specifically to the tumor without harming normal tissue.” SNNLive welcomes John Mon, COO of Medifocus Inc. For more information, check out their website at www.medifocusinc.com.
© 2017 Stock News Now
Supported by Superior Web Solutions